{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:37:51Z","timestamp":1789558671267,"version":"build-2803163510"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.2169\/internalmedicine.9011-21","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T22:10:32Z","timestamp":1647036632000},"page":"3239-3243","source":"Crossref","is-referenced-by-count":9,"title":["Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor"],"prefix":"10.2169","volume":"61","author":[{"given":"Yusuke","family":"Konta","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, JR Sendai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sendai City Hospital, Japan"},{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, and Research Division of Chronic Kidney Disease and Dialysis Treatment, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1: 140-151, 2013.","DOI":"10.1016\/S2213-8587(13)70050-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.","DOI":"10.1056\/NEJMoa1504720"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.","DOI":"10.1056\/NEJMoa1611925"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347-357, 2019.","DOI":"10.1056\/NEJMoa1812389"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323-334, 2016.","DOI":"10.1056\/NEJMoa1515920"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295-2306, 2019.","DOI":"10.1056\/NEJMoa1811744"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med 16: e1002983, 2019.","DOI":"10.1371\/journal.pmed.1002983"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 27: 1108-1113, 2017.","DOI":"10.1016\/j.numecd.2017.10.011"},{"key":"9","unstructured":"9. FDA Drug Safety Communication. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) [Internet]. 2016. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12: 711-712, 2016.","DOI":"10.1038\/nrneph.2016.159"},{"key":"11","unstructured":"11. Perlman A, Heyman SN, Stokar J, Darmon D, Muszkat M, Szalat A. Clinical spectrum and mechanism of acute kidney injury in patients with diabetes mellitus on SGLT-2 inhibitors. Isr Med Assoc J 20: 513-516, 2018."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Phadke G, Kaushal A, Tolan DR, et al. Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report. Am J Kidney Dis 76: 144-147, 2020.","DOI":"10.1053\/j.ajkd.2020.01.015"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pleros C, Stamataki E, Papadaki A, et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep 7: 17-20, 2018.","DOI":"10.1007\/s13730-017-0283-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bogdanffy MS, Stachlewitz RV, van Tongeren S, et al. Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol 33: 436-449, 2014.","DOI":"10.1177\/1091581814551648"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clin Kidney J 14: 1020-1022, 2021.","DOI":"10.1093\/ckj\/sfaa033"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kaku K, Chin R, Naito Y, et al. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf 19: 211-221, 2020.","DOI":"10.1080\/14740338.2020.1694659"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Watanabe S, Sawa N, Mizuno H, et al. Development of osmotic vacuolization of proximal tubular epithelial cells following treatment with sodium-glucose transport protein 2 inhibitors in type II diabetes mellitus patients-3 case reports. CEN Case Rep 10: 563-569, 2021.","DOI":"10.1007\/s13730-021-00609-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tang H, Li D, Zhang J, et al. Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 19: 1106-1115, 2017.","DOI":"10.1111\/dom.12917"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_9011-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:30:32Z","timestamp":1715315432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_9011-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":18,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9011-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"article-number":"9011-21"}}